Information letter to health care professionals regarding the medicinal product HEMOTRAN® (tranexamic acid). Intravenous forms of tranexamic acid – serious adverse reactions, including fatal ones, resulting from inadvertent intrathecal administration

23.01.2026 559 views

Інформаційний лист-звернення до спеціалістів системи охорони здоров’я щодо лікарського засобу ГЕМОТРАН®(транексамова кислота). Внутрішньовенні форми транексамової кислоти – серйозні, включно з летальними, побічні реакції внаслідок ненавмисного інтратекального введенняPDF · 1.1 МБ

Завантажити

Information letter to health care professionals regarding the medicinal product HEMOTRAN® (tranexamic acid). Intravenous forms of tranexamic acid – serious adverse reactions, including fatal ones, resulting from inadvertent intrathecal administration

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration

Information letter to health care professionals regarding the medicinal product HEMOTRAN® (tranexamic acid). Intravenous forms of tranexamic acid – serious adverse reactions, including fatal ones, resulting from inadvertent intrathecal administration

Other materials in this section

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration